Pluristem's successful stem cell trial last week on muscle injuries is an important first step for the company, says the company's CEO Zami Aberman. By using placental cells, Pluristem eliminates the ethical issues surrounding where the cells are derived, according to Aberman, who also touts his company's unique ability to manufacture 3D cells. Aberman is also bullish on Pluristem's partnership with United Therapeutics, another biotech company that has seen its shares spike in the past year.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

More from Video

Jim Cramer: I've Liked Six Flags Entertainment Stock as an Income Producer

Jim Cramer: I've Liked Six Flags Entertainment Stock as an Income Producer

Video: Jim Cramer Reveals Why He's Cautious on Stocks

Video: Jim Cramer Reveals Why He's Cautious on Stocks

Jim Cramer on Autonomous Driving Prowess of Texas Instruments

Jim Cramer on Autonomous Driving Prowess of Texas Instruments

Video: Jim Cramer on Caterpillar, Boeing, Twitter and Texas Instruments

Video: Jim Cramer on Caterpillar, Boeing, Twitter and Texas Instruments

Jim Cramer on Earnings: All Stories Aren't Equal

Jim Cramer on Earnings: All Stories Aren't Equal